Skip Navigation
Search Menu
Find an Expert

 


Nilofer Saba Azad, M.D.

Photo of Dr. Nilofer Saba Azad, M.D.

Associate Professor of Oncology

Female

Languages: English, Hindi, Urdu

Expertise: Anal Cancer, Bile Duct Cancer, Carcinoid Syndrome, Carcinoid Tumors, Cholangiocarcinoma, Clinical Trials, Colon Cancer, Colorectal Cancer, Gastric Cancer, Gastroesophageal Junction Cancer, Gastrointestinal Cancers, Gastrointestinal Tumors, Hepatocellular Cancer, Liver Cancer, Medical Oncology, Neuroendocrine Tumors, Pancreatic Cancer, Rectal Cancer, Small Bowel Cancer, Small Intestine Cancer, Stomach Cancer ...read more

Research Interests: GI Cancers: Colorectal, pancreatobiliary

Request an Appointment

I live in Maryland

410-955-8964
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-955-8893

Sibley Memorial Hospital
Appointment Phone: 202-660-6500

5255 Loughboro Road NW
Washington, DC 20016 map

Background

Dr. Nilofer S. Azad is an Associate Professor of oncology at Johns Hopkins University. Dr. Azad is board certified in medical oncology and practices out of John Hopkins Sidney Kimmel Cancer Center
 
Dr. Azad earned her medical degree from Baylor College of Medicine (BCM) in Houston, Texas. She continued her education at BCM, completing a residency in internal medicine.  She then went on to the National Cancer Institute at the National Institutes of Health in Bethesda, Maryland to complete a fellowship in oncology and hematology; she was named chief fellow during her time at the NCI.

Dr. Azad joined the faculty at the SKCCC at Johns Hopkins in 2008.  Dr. Azad’s clinical expertise is in cancers of the gastrointestinal tract, with a particular concentration in colorectal and pancreatobiliary cancer.  Her research efforts are dedicated to developing new drugs for patients with advanced cancer, with a focus on using epigenetic agents in combination with chemotherapy and immunotherapy to improve survival for patients.  She also has led multiple clinical trials of molecularly targeted agents for advanced cancer patients.  She has an active clinical trial portfolio, and serves as Director of the Phase I Clinical Trial Group. 

...read more

Titles

  • Associate Professor of Oncology

Departments / Divisions

Education

Degrees

  • MD, Baylor College of Medicine (2001)

Residencies

  • Baylor College of Medicine / Internal Medicine (2004)

Fellowships

  • National Cancer Institute- NIH / Oncology and Hematology (2008)

Board Certifications

  • American Board of Internal Medicine / Medical Oncology (2007)

Research & Publications

Clinical Trial Keywords

colorectal cancer, pancreatic cancer, cholangiocarcinoma, bile duct cancer

Selected Publications

View all on Pubmed

Reiss KA, Herman JM, Zahurak M, Brade A, Dawson LA, Scardina A, Joffe C,
Petito E, Hacker-Prietz A, Kinders RJ, Wang L, Chen A, Temkin S, Horiba N, Siu
LL, Azad NS. A Phase I study of veliparib (ABT-888) in combination with low-dose
fractionated whole abdominal radiation therapy in patients with advanced solid
malignancies and peritoneal carcinomatosis. Clin Cancer Res. 2015 Jan
1;21(1):68-76. doi: 10.1158/1078-0432.CCR-14-1552. Epub 2014 Oct 29. PubMed PMID:
25355929; PubMed Central PMCID: PMC428649

Pelosof L, Yerram SR, Ahuja N, Delmas A, Danilova L, Herman JG, Azad NS. CHFR
silencing or microsatellite instability is associated with increased antitumor
activity of docetaxel or gemcitabine in colorectal cancer. Int J Cancer. 2014 Feb
1;134(3):596-605. doi: 10.1002/ijc.28390. Epub 2013 Aug 24. PubMed PMID:
23873170; PubMed Central PMCID: PMC3830586.5

Azad N, Zahnow CA, Rudin CM, Baylin SB. The future of epigenetic therapy in solid tumours--lessons from the past. Nat Rev Clin Oncol. 2013 May;10(5):256-66. doi: 10.1038/nrclinonc.2013.42. Epub 2013 Apr 2. Review. PubMed PMID: 23546521;
PubMed Central PMCID: PMC3730253

Azad N, Dasari A, Arcaroli J, Taylor GE, Laheru DA, Carducci MA, McManus M, Quackenbush K, Wright JJ, Hidalgo M, Diaz LA Jr, Donehower RC, Zhao M, Rudek MA, Messersmith WA. Phase I pharmacokinetic and pharmacodynamic study of cetuximab,
rinotecan and sorafenib in advanced colorectal cancer. Invest New Drugs. 2013 Apr;31(2):345-54. doi: 10.1007/s10637-012-9820-z. Epub 2012 May 22. PubMed PMID: 22615057; PubMed Central PMCID: PMC3674958

Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol. 2008 Aug 1;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332. Erratum in: J Clin Oncol. 2008 Sep 10;26(26):4363. Figg, William D [added]. PubMed PMID: 18669456.

Is this you? Edit Profile